Silverfin false false 30/09/2024 01/10/2023 30/09/2024 Rob Misselbrook 08/10/2018 Alan James Sanders 30/09/2014 Dr Paul Martin Upton 30/09/2014 06 June 2025 The principal activity of the Company during the financial year was that of business and domestic software development. 09242021 2024-09-30 09242021 bus:Director1 2024-09-30 09242021 bus:Director2 2024-09-30 09242021 bus:Director3 2024-09-30 09242021 2023-09-30 09242021 core:CurrentFinancialInstruments 2024-09-30 09242021 core:CurrentFinancialInstruments 2023-09-30 09242021 core:ShareCapital 2024-09-30 09242021 core:ShareCapital 2023-09-30 09242021 core:SharePremium 2024-09-30 09242021 core:SharePremium 2023-09-30 09242021 core:RetainedEarningsAccumulatedLosses 2024-09-30 09242021 core:RetainedEarningsAccumulatedLosses 2023-09-30 09242021 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2023-09-30 09242021 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-09-30 09242021 core:OfficeEquipment 2023-09-30 09242021 core:ComputerEquipment 2023-09-30 09242021 core:OfficeEquipment 2024-09-30 09242021 core:ComputerEquipment 2024-09-30 09242021 2022-09-30 09242021 bus:OrdinaryShareClass1 2024-09-30 09242021 2023-10-01 2024-09-30 09242021 bus:FilletedAccounts 2023-10-01 2024-09-30 09242021 bus:SmallEntities 2023-10-01 2024-09-30 09242021 bus:AuditExemptWithAccountantsReport 2023-10-01 2024-09-30 09242021 bus:PrivateLimitedCompanyLtd 2023-10-01 2024-09-30 09242021 bus:Director1 2023-10-01 2024-09-30 09242021 bus:Director2 2023-10-01 2024-09-30 09242021 bus:Director3 2023-10-01 2024-09-30 09242021 core:DevelopmentCostsCapitalisedDevelopmentExpenditure core:TopRangeValue 2023-10-01 2024-09-30 09242021 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2023-10-01 2024-09-30 09242021 core:OfficeEquipment core:TopRangeValue 2023-10-01 2024-09-30 09242021 core:ComputerEquipment core:TopRangeValue 2023-10-01 2024-09-30 09242021 2022-10-01 2023-09-30 09242021 core:OfficeEquipment 2023-10-01 2024-09-30 09242021 core:ComputerEquipment 2023-10-01 2024-09-30 09242021 bus:OrdinaryShareClass1 2023-10-01 2024-09-30 09242021 bus:OrdinaryShareClass1 2022-10-01 2023-09-30 iso4217:GBP xbrli:pure xbrli:shares

Company No: 09242021 (England and Wales)

ULTRAMED LIMITED

Unaudited Financial Statements
For the financial year ended 30 September 2024
Pages for filing with the registrar

ULTRAMED LIMITED

Unaudited Financial Statements

For the financial year ended 30 September 2024

Contents

ULTRAMED LIMITED

STATEMENT OF FINANCIAL POSITION

As at 30 September 2024
ULTRAMED LIMITED

STATEMENT OF FINANCIAL POSITION (continued)

As at 30 September 2024
Note 2024 2023
£ £
Fixed assets
Intangible assets 3 850,421 643,468
Tangible assets 4 27,828 15,580
878,249 659,048
Current assets
Debtors 5 665,005 203,879
Cash at bank and in hand 335,791 830,708
1,000,796 1,034,587
Creditors: amounts falling due within one year 6 ( 862,559) ( 935,883)
Net current assets 138,237 98,704
Total assets less current liabilities 1,016,486 757,752
Provision for liabilities 7 ( 80,357) ( 19,461)
Net assets 936,129 738,291
Capital and reserves
Called-up share capital 8 57,946 57,816
Share premium account 484,839 484,839
Profit and loss account 393,344 195,636
Total shareholder's funds 936,129 738,291

For the financial year ending 30 September 2024 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The financial statements of Ultramed Limited (registered number: 09242021) were approved and authorised for issue by the Board of Directors on 06 June 2025. They were signed on its behalf by:

Dr Paul Martin Upton
Director
ULTRAMED LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 30 September 2024
ULTRAMED LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 30 September 2024
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

General information and basis of accounting

Ultramed Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is Ultramed Ltd, Tremough Innovation Centre, Penryn, TR10 9TA, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Going concern

The directors have assessed the Statement of Financial Position and likely future cash flows at the date of approving these financial statements. The directors have a reasonable expectation that the Company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

Foreign currency

Transactions in foreign currencies are recorded at the rate of exchange at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the Statement of Financial Position date are reported at the rates of exchange prevailing at that date.

Exchange differences are recognised in the Statement of Comprehensive Income in the period in which they arise except for exchange differences arising on gains or losses on non-monetary items which are recognised in the Statement of Comprehensive Income.

Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Turnover is recognised when the significant risks and rewards are considered to have been transferred to the customer.

Interest income

Interest income is recognised when it is probable that the economic benefits will flow to the Company and the amount of revenue can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

Employee benefits

Defined contribution schemes
The Company operates a defined contribution scheme. The amount charged to the Statement of Comprehensive Income in respect of pension costs and other post-retirement benefits is the contributions payable in the financial year. Differences between contributions payable in the financial year and contributions actually paid are included as either accruals or prepayments in the Statement of Financial Position.

Share-based payment

Equity-settled share-based payment transactions are measured at fair value at the date of grant. The fair value determined at the grant date of the equity-settled share-based payments is expensed on a straight-line basis over the vesting period, based on the Company’s estimate of shares that will eventually vest and adjusted for the effect of non-market-based vesting conditions.

Fair value is measured by use of the Black-Scholes model which is considered by management to be the most appropriate method of valuation. The expected life used in the model has been adjusted, based on management’s best estimate, for the effects of non-transferability, exercise restrictions, and behavioural considerations.

Cancellations or settlements (including those resulting from employee redundancies) are treated as an acceleration of vesting and the amount that would have been recognised over the remaining vesting period is recognised immediately.

Finance costs

Finance costs are charged to the Statement of Comprehensive Income over the term of the debt using the effective interest method so the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Statement of Financial Position date.

Deferred tax
Deferred tax arises as a result of including items of income and expenditure in taxation computations in periods different from those in which they are included in the Company's financial statements. Deferred tax is provided in full on timing differences which result in an obligation to pay more or less tax at a future date, at the average tax rates that are expected to apply when the timing differences reverse, based on current tax rates and laws. Deferred tax assets and liabilities are not discounted.

The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.

Intangible assets

Intangible assets are stated at cost or valuation, net of amortisation and any provision for impairment. Amortisation is provided on all intangible assets at rates to write off the cost or valuation of each asset over its expected useful life as follows:

Development costs 7 years straight line
Research and development

Research expenditure is written off as incurred. Development expenditure is also written off, except where the directors are satisfied as to the technical, commercial and financial viability of individual projects. In such cases, the identifiable expenditure is capitalised as an intangible asset and amortised over the period during which the Company is expected to benefit. This period is between three and five years. Provision is made for any impairment.

Tangible fixed assets

Tangible fixed assets are stated at cost (or deemed cost) or valuation less accumulated depreciation and accumulated impairment losses. Cost includes costs directly attributable to making the asset capable of operating as intended. Depreciation is provided on all tangible fixed assets, other than investment properties and freehold land, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a straight-line basis over its expected useful life, as follows:

Office equipment 7 years straight line
Computer equipment 5 years straight line

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.

Impairment of assets

Assets, other than those measured at fair value, are assessed for indicators of impairment at each Statement of Financial Position date. If there is objective evidence of impairment, an impairment loss is recognised in the Statement of Comprehensive Income as described below.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts, except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in creditors: amounts falling due within one year.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Financial instruments

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

Financial assets and liabilities are only offset in the Balance Sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the Company intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Government grants

Government grants are recognised based on the accrual model and are measured at the fair value of the asset received or receivable. Grants are classified as relating either to revenue or to assets. Grants relating to revenue are recognised in income over the period in which the related costs are recognised. Grants relating to assets are recognised over the expected useful life of the asset. Where part of a grant relating to an asset is deferred, it is recognised as deferred income.

Ordinary share capital

The ordinary share capital of the Company is presented as equity.

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.

2. Employees

2024 2023
Number Number
Monthly average number of persons employed by the Company during the year, including directors 18 15

3. Intangible assets

Development costs Total
£ £
Cost
At 01 October 2023 852,436 852,436
Additions 360,688 360,688
At 30 September 2024 1,213,124 1,213,124
Accumulated amortisation
At 01 October 2023 208,968 208,968
Charge for the financial year 153,735 153,735
At 30 September 2024 362,703 362,703
Net book value
At 30 September 2024 850,421 850,421
At 30 September 2023 643,468 643,468

4. Tangible assets

Office equipment Computer equipment Total
£ £ £
Cost
At 01 October 2023 3,407 30,276 33,683
Additions 0 18,291 18,291
At 30 September 2024 3,407 48,567 51,974
Accumulated depreciation
At 01 October 2023 1,701 16,402 18,103
Charge for the financial year 303 5,740 6,043
At 30 September 2024 2,004 22,142 24,146
Net book value
At 30 September 2024 1,403 26,425 27,828
At 30 September 2023 1,706 13,874 15,580

5. Debtors

2024 2023
£ £
Trade debtors 571,322 87,540
Prepayments 56,368 44,489
Corporation tax 37,315 71,850
665,005 203,879

6. Creditors: amounts falling due within one year

2024 2023
£ £
Trade creditors 4,852 42,249
Accruals and deferred income 660,935 779,250
Other taxation and social security 176,344 89,901
Other creditors 20,428 24,483
862,559 935,883

7. Deferred tax

2024 2023
£ £
At the beginning of financial year ( 19,461) 56,150
Charged to the Profit and Loss Account ( 60,896) ( 75,611)
At the end of financial year ( 80,357) ( 19,461)

8. Called-up share capital

2024 2023
£ £
Allotted, called-up and fully-paid
5,794,611 Ordinary shares of £ 0.01 each (2023: 5,781,611 shares of £ 0.01 each) 57,946 57,816

In the financial year 2024 class Ordinary shares were allotted with an aggregate nominal value of £130.